Inflammatory disorders of the central nervous system.

[1]  V. Kepe,et al.  In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile , 2003, Neuroscience.

[2]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.

[3]  Xiao-Fen Wang,et al.  Studies characterizing 60 kda autoantibodies in subjects with schizophrenia , 2003, Biological Psychiatry.

[4]  R. Hohlfeld,et al.  Neurotrophic cross‐talk between the nervous and immune systems: Implications for neurological diseases , 2003, Annals of neurology.

[5]  K. Buller.  Neuroimmune Stress Responses: Reciprocal Connections Between the Hypothalamus and the Brainstem , 2003, Stress.

[6]  R. Hohlfeld,et al.  Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. , 2002, Brain : a journal of neurology.

[7]  H. Stefánsson,et al.  Neuregulin 1 and susceptibility to schizophrenia. , 2002, American journal of human genetics.

[8]  S. Larson.  Behavioral and Motivational Effects of Immune-System Activation , 2002, The Journal of general psychology.

[9]  P. Zandi,et al.  Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study , 2002, Neurology.

[10]  N. V. Chandrasekharan,et al.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[11]  V. Perry,et al.  Peripheral infection evokes exaggerated sickness behaviour in pre-clinical murine prion disease , 2002, Neuroscience.

[12]  M. Pierer,et al.  Immunopathogenesis of Rheumatic Diseases in the Context of Neuroendocrine Interactions , 2002, Annals of the New York Academy of Sciences.

[13]  C. Adler,et al.  Paraneoplastic chorea associated with CRMP‐5 neuronal antibody and lung carcinoma , 2002, Annals of neurology.

[14]  Akira Sawa,et al.  Schizophrenia: Diverse Approaches to a Complex Disease , 2002, Science.

[15]  R. Gómez,et al.  Antibodies Against Cerebral M1 Cholinergic Muscarinic Receptor from Schizophrenic Patients: Molecular Interaction1 , 2002, The Journal of Immunology.

[16]  W. Potts,et al.  Discrimination of MHC-derived odors by untrained mice is consistent with divergence in peptide-binding region residues , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Dalmau,et al.  Response to cancer therapy in a patient with a paraneoplastic choreiform disorder , 2001, Neurology.

[18]  M J Owen,et al.  Searching for schizophrenia genes. , 2001, Trends in molecular medicine.

[19]  E. Benarroch,et al.  CRMP‐5 neuronal autoantibody: Marker of lung cancer and thymoma‐related autoimmunity , 2001, Annals of neurology.

[20]  J. Hardy,et al.  Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.

[21]  Ralph A. Nixon,et al.  Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.

[22]  Y. Piao,et al.  Chorea resulting from paraneoplastic striatal encephalitis , 2000, Journal of neurology, neurosurgery, and psychiatry.

[23]  U. Bonuccelli,et al.  Paraneoplastic choreic syndrome during non‐Hodgkin's lymphoma , 2000, Movement disorders : official journal of the Movement Disorder Society.

[24]  M. Schwarz,et al.  The Immune System and Schizophrenia: An Integrative View , 2000, Annals of the New York Academy of Sciences.

[25]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[26]  A. Druschky,et al.  Chorea resulting from paraneoplastic encephalitis , 1997, Movement disorders : official journal of the Movement Disorder Society.

[27]  B. Rabin,et al.  An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia , 1994, Psychological Medicine.

[28]  M. Shinitzky,et al.  Platelet Autoantibodies in Dementia and Schizophrenia , 1991 .

[29]  R. Ganguli,et al.  Clinical and Laboratory Evidence of Autoimmunity in Acute Schizophrenia , 1987, Annals of the New York Academy of Sciences.

[30]  L. DeLisi,et al.  Are there antibodies against brain in sera from schizophrenic patients? Review and prospectus , 1985, Biological Psychiatry.

[31]  R. Ries.  Poor interrater reliability of MECTA EEG seizure duration measurement during ECT , 1985, Biological Psychiatry.

[32]  G. Hunter,et al.  Chorea as a paraneoplastic complication of Hodgkin's disease , 2004, Journal of Neuro-Oncology.

[33]  M. Schwarz,et al.  Autoantibodies against 60-kDa heat shock protein in schizophrenia , 1998, European Archives of Psychiatry and Clinical Neuroscience.

[34]  Y. Shoenfeld,et al.  Autoantibodies to brain and polynucleotides in patients with schizophrenia: A puzzle , 1992, Immunologic research.

[35]  J. Penney,et al.  Chorea and dystonia: A remote effect of carcinoma , 1988, Movement disorders : official journal of the Movement Disorder Society.

[36]  R. Heath,et al.  Schizophrenia as an Immunologic Disorder: II. Effects of Serum Protein Fractions on Brain Function , 1967 .